Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Loss Drug to Irreversible Blindness A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

SJM's Hostess acquisition doubled debt and led to impairments; company is prioritizing $500M annual debt repayment and ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

She recommends women undergo a “baseline” dual-energy X-ray absorptiometry (DEXA) scan in their early to mid-30s to help ...

Chinese drugmaker Guangzhou Innogen Pharmaceutical had a strong debut in Hong Kong, cashing in on positive sentiment toward its flagship drug and Chinese biotech stocks in general.

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

Tiny "hidden" proteins lurking in DNA once dismissed as junk may hold the key to the next generation of obesity drugs, ...

Current weight-loss and diabetes medications, such as GLP-1 drugs, often fail to deliver lasting results and are plagued by ...